Previous 10 | Next 10 |
AbCellera Biologics reported Q2 numbers that were not all that impressive; however, the news of the commercialization agreement its partner Lilly inked has driven shares to near YTD highs. The commercialization plan looks to provide AbCellera with continued non-dilutive funding to fur...
Shares of AbCellera Biologics ( NASDAQ: ABCL ) gained 16.7% to $12.98 in Wednesday afternoon trading, as investors looked past the company's Q2 results miss to focus on continued strength from COVID-19 royalties and a sustained increase in discovery programs. ABCL after ...
Shares of biopharmaceutical developer AbCellera Biologics (NASDAQ: ABCL) are up 19.1% as of 11:51 a.m. ET Wednesday, according to data from S&P Global Market Intelligence , down from its midday peak near 23.7%. The surge follows yesterday's post-close release of mixed second...
Image source: The Motley Fool. AbCellera Biologics Inc. (NASDAQ: ABCL) Q2 2022 Earnings Call Aug 09, 2022 , 5:00 p.m. ET Operator Continue reading For further details see: AbCellera Biologics Inc. (ABCL) Q2 2022 Earnings Call Transcript ...
AbCellera Biologics Inc. (ABCL) Q2 2022 Earnings Conference Call August 09, 2022, 05:00 PM ET Company Participants Tryn Stimart - Chief Legal and Compliance Officer Dr. Carl Hansen - President and CEO Andrew Booth - CFO Conference Call Participants Ti...
The following slide deck was published by AbCellera Biologics Inc. in conjunction with their 2022 Q2 earnings call. For further details see: AbCellera Biologics Inc. 2022 Q2 - Results - Earnings Call Presentation
AbCellera Biologics press release ( NASDAQ: ABCL ): Q2 GAAP EPS of -$0.02 misses by $0.03 . Revenue of $45.6M (+65.2% Y/Y) misses by $15.62M . $1,022M of cash, cash equivalents, and marketable securities. For further details see: AbCellera Biologics G...
Total revenue of $46 million, compared to $28 million in Q2 2021 Four program starts in the quarter bringing cumulative total to 88, up 47% from Q2 2021 Net loss of ($0.02) per share on a basic and diluted basis compared to ($0.01) (basic and diluted) per share in Q2...
Eli Lilly ( NYSE: LLY ) announced that the FDA had updated the authorization granted for its COVID-19 antibody therapy bebtelovimab allowing its commercial availability from next week through the drug distributor AmerisourceBergen ( ABC ). Per the previous authorizatio...
AbCellera Biologics ( NASDAQ: ABCL ) has entered into a partnership with Atlas Ventures to discover therapeutic antibodies for up to three drug targets . Terms call for Atlas to have the right to develop and commercialize therapeutic antibodies resulting from the colla...
News, Short Squeeze, Breakout and More Instantly...
AbCellera Biologics Inc. Company Name:
ABCL Stock Symbol:
NASDAQ Market:
AbCellera Biologics Inc. Website:
AbCellera (Nasdaq: ABCL) will announce its second quarter 2024 financial results on Tuesday, August 6, 2024, and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) the same day. A live audio webcast of the earnings conference may be accessed through a link t...
2024-06-13 05:40:00 ET Discovering new drugs can be a lucrative endeavor, but things aren't working out lately for AbCellera Biologics (NASDAQ: ABCL) . Shares of this unusual biotech stock are down by about 57% from the high water mark they set last summer. The steep losses migh...
AbCellera (Nasdaq: ABCL) today announced that executives from the Company will present at the Goldman Sachs 45th Annual Global Healthcare Conference on Monday, June 10, 2024, at 12:20 p.m. Pacific Time (3:20 p.m. Eastern Time). A live audio webcast of the presentation may be accessed throug...